Tech • IA • Crypto
đź”´ Alex Karp Live from AIPCon 10
8/10TL;DR
AI and biotech leaders are urging mandatory DNA synthesis screening to counter rising biosecurity risks amplified by AI, as investment surges across tech and life sciences.
KEY POINTS
Industry unites over AI-driven biosecurity risks
Prominent figures including Demis Hassabis, Sam Altman, Dario Amodei, and Alex Wang have signed a joint letter calling for stricter oversight of nucleic acid synthesis. The proposal focuses on mandatory screening of genetic orders, customer verification, and recordkeeping to prevent misuse. The initiative reflects growing concern that AI tools could lower the barrier to designing harmful biological agents.
From open science to potential threat vector
Historical precedents highlight the risk: the polio virus genome was published in 1981, and by 2002 scientists recreated the virus using only its sequence. Similarly, the 1918 Spanish flu was reconstructed in 2005. These breakthroughs demonstrated that physical samples are no longer required—genetic “blueprints” alone can enable virus synthesis.
AI accelerates biological capabilities
Advances in AI are expected to make designing novel or modified genetic sequences faster and more accessible. While current models cannot instantly generate dangerous pathogens, leaders warn that the trajectory points toward increasing capability. The concern is not hypothetical breakthroughs but the compounding ease of combining AI design with widely available synthesis services.
Voluntary safeguards seen as insufficient
About 80% of global DNA synthesis capacity participates in voluntary screening through the International Gene Synthesis Consortium, established in 2009. However, compliance is self-reported and not enforced, leaving gaps in oversight. The remaining 20% of providers, along with inconsistent adherence, represents a significant vulnerability.
Policy push targets enforceable regulation
The letter calls on governments, particularly the United States, to formalize requirements for screening and tracking genetic orders. Existing guidance from agencies like HHS remains voluntary, limiting its effectiveness. Advocates argue that enforceable standards are necessary as AI increases both the scale and sophistication of potential misuse.
Biotech investment momentum returns
Alongside security concerns, biotech is experiencing renewed activity after a period of weak returns. Companies such as Isomorphic Labs, NewLimit, Altos Labs, and Retro Biosciences are attracting capital and attention. While still smaller in scale than AI investments, the sector is regaining momentum with a mix of large bets and frequent mid-sized exits.
Ramp raises $750 million at $44 billion valuation
Fintech firm Ramp secured $750 million in new funding, reaching a $44 billion valuation. The company highlighted rapid growth, noting it is expanding faster than when it was “1/120th the size.” The valuation surpasses some legacy players despite far lower revenue, reflecting investor preference for high-growth platforms over mature incumbents.
Benchmark launches first growth fund
Venture firm Benchmark raised $2 billion across new funds, including its first dedicated growth vehicle. The move signals a strategic shift beyond early-stage investing, aligning with broader industry trends toward capturing value across longer company lifecycles.
CONCLUSION
As AI reshapes both opportunity and risk, leaders are pushing for stricter biosecurity safeguards while capital continues flowing into high-growth tech and biotech ventures.